High content drug screening of primary cardiomyocytes based on microfluidics and real-time ultra-large-scale high-resolution imaging

Leveraging advances in microfluidics and imaging technology, we setup a new paradigm of large-scale, high-content drug screening solutions for rapid biological processes, like cardiotoxicity.